吉大正元(003029.SZ):國投高科擬以集中競價減持不超2%的股份
格隆匯11月23日丨吉大正元(003029.SZ)公佈,國投高科技投資有限公司(“國投高科”)自2022年9月19日起不再為公司持股5%以上股東,此次集中競價交易減持計劃擬首次減持時間距離前述時間節點未超過90個自然日,國投高科仍需遵循針對持股5%以上股東的減持披露要求,對減持計劃進行預披露。
在減持期間內通過集中競價交易減持不超過372.694萬股股份(佔公司總股本的2%),在任意連續90個自然日之內,通過集中競價減持不超過公司總股本的1%(若減持期間出現送股、資本公積金轉增股本等股份變動事項,則對上述減持數量進行相應調整)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.